-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
CIBC Asset Management Inc Purchases Shares of 5,711 Novartis AG (NYSE:NVS)
CIBC Asset Management Inc Purchases Shares of 5,711 Novartis AG (NYSE:NVS)
CIBC Asset Management Inc purchased a new position in shares of Novartis AG (NYSE:NVS – Get Rating) in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 5,711 shares of the company's stock, valued at approximately $501,000.
Other institutional investors and hedge funds have also recently bought and sold shares of the company. AHL Investment Management Inc. acquired a new stake in shares of Novartis during the fourth quarter worth $25,000. Atwood & Palmer Inc. increased its stake in Novartis by 400.0% during the 1st quarter. Atwood & Palmer Inc. now owns 375 shares of the company's stock valued at $33,000 after buying an additional 300 shares during the period. Allegheny Financial Group LTD acquired a new position in Novartis during the 4th quarter valued at about $34,000. DeDora Capital Inc. bought a new position in shares of Novartis during the 1st quarter valued at about $34,000. Finally, Tyler Stone Wealth Management bought a new position in shares of Novartis during the 4th quarter valued at about $39,000. Institutional investors and hedge funds own 9.40% of the company's stock.
Get Novartis alerts:Novartis Stock Up 1.4 %
NVS opened at $87.15 on Wednesday. Novartis AG has a 1-year low of $79.09 and a 1-year high of $95.17. The stock's fifty day simple moving average is $84.85 and its 200 day simple moving average is $86.58. The company has a current ratio of 1.38, a quick ratio of 1.13 and a debt-to-equity ratio of 0.35. The stock has a market cap of $192.83 billion, a PE ratio of 8.52, a price-to-earnings-growth ratio of 2.42 and a beta of 0.51.
Novartis (NYSE:NVS – Get Rating) last released its earnings results on Monday, July 18th. The company reported $1.56 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.52 by $0.04. The company had revenue of $12.78 billion for the quarter, compared to analyst estimates of $12.78 billion. Novartis had a return on equity of 21.88% and a net margin of 44.31%. Novartis's quarterly revenue was down 1.4% on a year-over-year basis. During the same period in the prior year, the firm posted $1.64 EPS. As a group, research analysts expect that Novartis AG will post 6.06 earnings per share for the current year.Wall Street Analysts Forecast Growth
Several research analysts have commented on the stock. Credit Suisse Group raised their target price on shares of Novartis from CHF 85 to CHF 88 in a report on Thursday, April 28th. Morgan Stanley raised their price objective on shares of Novartis from CHF 90 to CHF 94 in a research report on Friday, May 6th. Oppenheimer lowered shares of Novartis from an "outperform" rating to a "market perform" rating in a research report on Friday, June 3rd. Wolfe Research lowered shares of Novartis from an "outperform" rating to a "market perform" rating in a research report on Monday, May 9th. Finally, upgraded shares of Novartis from a "hold" rating to a "buy" rating in a research note on Thursday, April 14th. Two analysts have rated the stock with a sell rating, eight have issued a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, Novartis presently has a consensus rating of "Hold" and a consensus target price of $87.33.
Novartis Profile
(Get Rating)
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products.
Further Reading
- Get a free copy of the StockNews.com research report on Novartis (NVS)
- Are 3M, Honeywell, GE Buys After Quarterly Reports?
- This Defense Stock Has Bullish Fundamentals AND Technicals
- CVS and Walgreens Show Why Investment Objectives Matter
- Is Sofi Financial Stock Finally Ready to Pay Off for Investors?
- Are Medtronic And Intuitive Surgical Poised For Big Growth?
Want to see what other hedge funds are holding NVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novartis AG (NYSE:NVS – Get Rating).
Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.
CIBC Asset Management Inc purchased a new position in shares of Novartis AG (NYSE:NVS – Get Rating) in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 5,711 shares of the company's stock, valued at approximately $501,000.
根据加拿大帝国商业银行资产管理公司在第一季度购买了诺华制药(纽约证券交易所代码:NVS-GET评级)的新股票头寸,根据该公司向美国证券交易委员会(美国证券交易委员会)的最新披露。该机构投资者购买了5711股该公司股票,价值约501,000美元。
Other institutional investors and hedge funds have also recently bought and sold shares of the company. AHL Investment Management Inc. acquired a new stake in shares of Novartis during the fourth quarter worth $25,000. Atwood & Palmer Inc. increased its stake in Novartis by 400.0% during the 1st quarter. Atwood & Palmer Inc. now owns 375 shares of the company's stock valued at $33,000 after buying an additional 300 shares during the period. Allegheny Financial Group LTD acquired a new position in Novartis during the 4th quarter valued at about $34,000. DeDora Capital Inc. bought a new position in shares of Novartis during the 1st quarter valued at about $34,000. Finally, Tyler Stone Wealth Management bought a new position in shares of Novartis during the 4th quarter valued at about $39,000. Institutional investors and hedge funds own 9.40% of the company's stock.
其他机构投资者和对冲基金最近也买卖了该公司的股票。AHL投资管理公司在第四季度收购了价值25,000美元的诺华新股。今年第一季度,阿特伍德-帕尔默公司增持诺华股份400.0%。Atwood&Palmer Inc.现在持有375股该公司股票,价值33,000美元,在此期间又购买了300股。阿勒格尼金融集团有限公司在第四季度收购了诺华公司的一个新头寸,价值约3.4万美元。DeDora Capital Inc.在第一季度购买了新的诺华股票头寸,价值约3.4万美元。最后,泰勒·斯通财富管理公司在第四季度购买了新的诺华股票头寸,价值约3.9万美元。机构投资者和对冲基金持有该公司9.40%的股票。
Novartis Stock Up 1.4 %
诺华公司股价上涨1.4%
NVS opened at $87.15 on Wednesday. Novartis AG has a 1-year low of $79.09 and a 1-year high of $95.17. The stock's fifty day simple moving average is $84.85 and its 200 day simple moving average is $86.58. The company has a current ratio of 1.38, a quick ratio of 1.13 and a debt-to-equity ratio of 0.35. The stock has a market cap of $192.83 billion, a PE ratio of 8.52, a price-to-earnings-growth ratio of 2.42 and a beta of 0.51.
NVS周三开盘报87.15美元。诺华制药的一年低点为79.09美元,一年高位为95.17美元。该股的50日简单移动均线为84.85美元,200日简单移动均线为86.58美元。该公司的流动比率为1.38,速动比率为1.13,债务权益比率为0.35。该股市值为1,928.3亿美元,市盈率为8.52倍,市盈率为2.42倍,贝塔系数为0.51。
Wall Street Analysts Forecast Growth
华尔街分析师预测经济增长
Several research analysts have commented on the stock. Credit Suisse Group raised their target price on shares of Novartis from CHF 85 to CHF 88 in a report on Thursday, April 28th. Morgan Stanley raised their price objective on shares of Novartis from CHF 90 to CHF 94 in a research report on Friday, May 6th. Oppenheimer lowered shares of Novartis from an "outperform" rating to a "market perform" rating in a research report on Friday, June 3rd. Wolfe Research lowered shares of Novartis from an "outperform" rating to a "market perform" rating in a research report on Monday, May 9th. Finally, upgraded shares of Novartis from a "hold" rating to a "buy" rating in a research note on Thursday, April 14th. Two analysts have rated the stock with a sell rating, eight have issued a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, Novartis presently has a consensus rating of "Hold" and a consensus target price of $87.33.
几位研究分析师对该股发表了评论。瑞士信贷集团在4月28日星期四的一份报告中将诺华公司股票的目标价从85瑞士法郎上调至88瑞士法郎。摩根士丹利在5月6日星期五的一份研究报告中将诺华公司的股票目标价从90瑞士法郎上调至94瑞士法郎。在6月3日星期五的一份研究报告中,奥本海默将诺华公司的股票评级从“跑赢大盘”下调至“市场表现”。沃尔夫研究公司在5月9日星期一的一份研究报告中将诺华公司的股票评级从“跑赢大盘”下调至“市场表现”。最后,在4月14日星期四的一份研究报告中,诺华公司的股票评级从持有上调至买入。两名分析师对该股的评级为卖出,八名分析师发布了持有评级,三名分析师发布了买入评级,一名分析师对该股给予了强烈的买入评级。根据MarketBeat的数据,诺华目前的共识评级为持有,共识目标价为87.33美元。
Novartis Profile
诺华简介
(Get Rating)
(获取评级)
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products.
诺华制药在全球研究、开发、制造和营销保健品。该公司通过两个部门运营,创新药品和Sandoz。创新药品部门为患者和医疗保健提供者提供处方药。它还提供眼科、神经科学、免疫学、肝科、皮肤科、呼吸科、心血管、肾脏和新陈代谢药物产品。
Further Reading
进一步阅读
- Get a free copy of the StockNews.com research report on Novartis (NVS)
- Are 3M, Honeywell, GE Buys After Quarterly Reports?
- This Defense Stock Has Bullish Fundamentals AND Technicals
- CVS and Walgreens Show Why Investment Objectives Matter
- Is Sofi Financial Stock Finally Ready to Pay Off for Investors?
- Are Medtronic And Intuitive Surgical Poised For Big Growth?
- 免费获取StockNews.com关于诺华(Novartis)的研究报告
- 3M、霍尼韦尔、通用电气在季度报告后收购吗?
- 这只国防股票的基本面和技术面都看涨
- CVS和Walgreens展示为什么投资目标很重要
- 索菲金融股票终于准备好为投资者买单了吗?
- 美敦力和直觉外科公司准备实现大增长吗?
Want to see what other hedge funds are holding NVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novartis AG (NYSE:NVS – Get Rating).
想看看其他对冲基金持有哪些NVS吗?访问HoldingsChannel.com获取诺华制药(纽约证券交易所代码:NVS-GET Rating)的最新13F文件和内幕交易信息。
Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.
接受诺华日报的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对诺华和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧